Yu‐Chuan Yan

机构：China Iron and Steel Research Institute Group, Beijing Water Science and Technology Institute, Qilu Hospital of Shandong University · ORCID：0000-0002-3233-8204

发表论文 64 篇 · 总被引 786 次 · h-index 16

代表论文

Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis (2024 · The Oncologist · 被引 26)
Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response (2025 · Metabolism · 被引 11)
DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression (2024 · Cell Death and Disease · 被引 11)
Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolism (2025 · Cell Death Discovery · 被引 10)
Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma (2025 · Cell Death and Disease · 被引 5)
Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis (2024 · Journal of Gastroenterology and Hepatology · 被引 5)